Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1995 1
1996 1
1997 2
1999 2
2000 2
2001 3
2002 1
2003 3
2004 1
2005 1
2006 1
2007 2
2008 4
2009 5
2010 2
2011 4
2012 4
2013 6
2014 4
2015 5
2016 3
2017 5
2018 2
2020 2
2021 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

62 results
Results by year
Filters applied: . Clear all
Page 1
PRMT5 as a druggable target for glioblastoma therapy.
Banasavadi-Siddegowda YK, Welker AM, An M, Yang X, Zhou W, Shi G, Imitola J, Li C, Hsu S, Wang J, Phelps M, Zhang J, Beattie CE, Baiocchi R, Kaur B. Banasavadi-Siddegowda YK, et al. Among authors: beattie ce. Neuro Oncol. 2018 May 18;20(6):753-763. doi: 10.1093/neuonc/nox206. Neuro Oncol. 2018. PMID: 29106602 Free PMC article.
Early pressure screens.
Beattie CE, Raible DW, Henion PD, Eisen JS. Beattie CE, et al. Methods Cell Biol. 1999;60:71-86. Methods Cell Biol. 1999. PMID: 9891331 Review. No abstract available.
ΔNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma.
Cam M, Charan M, Welker AM, Dravid P, Studebaker AW, Leonard JR, Pierson CR, Nakano I, Beattie CE, Hwang EI, Kambhampati M, Nazarian J, Finlay JL, Cam H. Cam M, et al. Among authors: beattie ce. Neuro Oncol. 2020 Mar 5;22(3):345-356. doi: 10.1093/neuonc/noz190. Neuro Oncol. 2020. PMID: 31763674 Free PMC article.
62 results